• Announcement or News
  • November 13, 2020

Emergency Use Authorization for Bamlanivimab

Bamlanivimab is now authorized for the treatment of mild to moderate COVID-19 in outpatient adults and pediatric patients 12 years and older weighing more than 88 pounds (40 kg) with a positive COVID-19 test, who are at high risk for progressing to severe COVID-19 and/or hospitalization.

More info from Food & Drug Administration: Coronavirus (COVID-19) Update: November 9, 2020